BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15767557)

  • 1. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
    Mongan NP; Gudas LJ
    Mol Cancer Ther; 2005 Mar; 4(3):477-86. PubMed ID: 15767557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
    Sirchia SM; Ferguson AT; Sironi E; Subramanyan S; Orlandi R; Sukumar S; Sacchi N
    Oncogene; 2000 Mar; 19(12):1556-63. PubMed ID: 10734315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
    Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
    Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
    PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
    Bovenzi V; Momparler RL
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):71-6. PubMed ID: 11488527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
    Primeau M; Gagnon J; Momparler RL
    Int J Cancer; 2003 Jan; 103(2):177-84. PubMed ID: 12455031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
    Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of valproic acid and ATRA restores RARβ2 expression and induces differentiation in cervical cancer through the PI3K/Akt pathway.
    Feng D; Cao Z; Li C; Zhang L; Zhou Y; Ma J; Liu R; Zhou H; Zhao W; Wei H; Ling B
    Curr Mol Med; 2012 Mar; 12(3):342-54. PubMed ID: 22229477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
    Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
    Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.
    Youssef EM; Chen XQ; Higuchi E; Kondo Y; Garcia-Manero G; Lotan R; Issa JP
    Cancer Res; 2004 Apr; 64(7):2411-7. PubMed ID: 15059893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
    Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
    Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
    Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
    Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.
    Sirchia SM; Ren M; Pili R; Sironi E; Somenzi G; Ghidoni R; Toma S; Nicolò G; Sacchi N
    Cancer Res; 2002 May; 62(9):2455-61. PubMed ID: 11980632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
    Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
    Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
    Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
    Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
    Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
    Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
    Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
    Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
    Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
    Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.